Figure 5
From: LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats
Effect of valsartan and LCZ696 on the mRNA expression of collagen, tumor necrosis factor-alpha (TNFa), and atrial natriuretic peptide (ANP) in the rat heart, and on serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in DOX-treated rats. (A) Real-time PCR to check for the expression of COL1A1 mRNA on day 18. The DOX-induced increase in the mRNA levels of COL1A1 was significantly suppressed by LCZ, but not VAL. n = 10–15 in each group. (B) Real-time PCR analysis of TNFa mRNA on day 18. The DOX-induced increase in the mRNA levels of TNFa was not reduced by VAL or LCZ significantly. n = 10–15 in each group. (C) Real-time PCR to check for the expression of ANP mRNA on day 18. The DOX-induced increase in the mRNA levels of ANP was significantly suppressed by VAL or LCZ. n = 10–15 in each group. (D) Serum NT-proBNP level was significantly increased upon DOX treatment. LCZ, but not VAL, significantly reduced the serum NT-proBNP levels that were increased upon DOX treatment. n = 10–15 in each group. Data are expressed as the mean ± standard error. *p < 0.05 versus control and #p < 0.05 versus DOX. DOX, doxorubicin; VAL, valsartan; LCZ, LCZ696; COL1A1, collagen type I alpha 1; TNFa, tumor necrosis factor-alpha; ANP, atrial natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide.
